PLEASANTON, Calif., Oct. 29, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of expanded claims for the cobas® EGFR Mutation ...
HILDEN, Germany, and TOKYO--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the Japanese Pharmaceuticals and Medical Device Agency (PMDA) has approved the ...
MISSION HILLS, LOS ANGELES (KABC) -- A medical test for kidney function that adjusts its results for race is coming under increased scrutiny. Experts are saying the results for African-American ...
Development of an automated RNA-based nuclease protection assay for the detection of expressed EML-ALK fusions, EGFR, and KRAS mutations in NSCLC. This is an ASCO Meeting Abstract from the 2013 ASCO ...
A race-specific algorithm designed to assess kidney function for individuals awaiting transplants jeopardized critical treatment for some Black Americans. An exclusive report by the Associated Press ...
CHICAGO -- There is new hope for thousands of African Americans waiting for a new kidney. A test to determine placement on a transplant waiting list has been deemed flawed. The finding will have a ...
In recent years, the medical community, researchers, and health policy makers have increasingly recognized that many long-established and widely used clinical decision-making tools actually perpetuate ...
- Lung cancer causes more than 1.7 million deaths worldwide each year, with NSCLC accounting for about 85 percent of all cases[1] - The cobas EGFR Mutation Test v2 is FDA approved as a companion ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback